Next 10 |
Venlo, the Netherlands, May 14, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced an updated version of its clinical decision support platform, QIAGEN Clinical Insight Interpret for NGS molecular profiling of hereditary and somatic diseases, has received ...
2024-05-13 14:06:05 ET More on Qiagen Qiagen N.V. 2024 Q1 - Results - Earnings Call Presentation Qiagen N.V. (QGEN) Q1 2024 Earnings Call Transcript QIAGEN to collaborate with FBI on forensic PCR test Qiagen Non-GAAP EPS of $0.46 beats by $0.02, revenue of $4...
Germantown, Maryland, and Venlo, the Netherlands, May 13, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Respiratory Panel Plus syndromic test for clinical use. The QIAstat...
2024-05-07 17:12:05 ET More on Qiagen Qiagen N.V. 2024 Q1 - Results - Earnings Call Presentation Qiagen N.V. (QGEN) Q1 2024 Earnings Call Transcript Qiagen N.V. 2023 Q4 - Results - Earnings Call Presentation Qiagen Non-GAAP EPS of $0.46 beats by $0.02, revenu...
Venlo, the Netherlands, and Washington, D.C., May 07, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a cooperative research and development agreement (CRADA) with the U.S. Federal Bureau of Investigation (FBI) to develop a novel test for its QIAcuity d...
2024-05-06 15:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Venlo, the Netherlands, and Redwood City, California, May 02, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the availability of QCI Secondary Analysis, a cloud-based software-as-a-services (SaaS) solution enabling high-throughput secondary analy...
2024-04-30 15:27:02 ET Qiagen N.V. (QGEN) Q1 2024 Earnings Conference Call April 30, 2024, 09:00 AM ET Company Participants John Gilardi - VP, Corporate Communications & IR Thierry Bernard - Chief Executive Officer Roland Sackers - Chief Financial Officer ...
2024-04-29 16:23:17 ET More on Qiagen Qiagen N.V. 2023 Q4 - Results - Earnings Call Presentation Qiagen N.V. (QGEN) Q4 2023 Earnings Call Transcript Qiagen Q1 2024 Earnings Preview Bio-Techne and Qiagen had the biggest increase in short interest levels last m...
Venlo, the Netherlands, April 29, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for the first quarter of 2024. Net sales declined 5% to $459 million, while results at constant exchanges rates (CER) of $462 million were above the outlo...
News, Short Squeeze, Breakout and More Instantly...
Qiagen N.V. Company Name:
QGEN Stock Symbol:
NYSE Market:
Venlo, the Netherlands, May 14, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced an updated version of its clinical decision support platform, QIAGEN Clinical Insight Interpret for NGS molecular profiling of hereditary and somatic diseases, has received ...
Germantown, Maryland, and Venlo, the Netherlands, May 13, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Respiratory Panel Plus syndromic test for clinical use. The QIAstat...
Venlo, the Netherlands, and Washington, D.C., May 07, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a cooperative research and development agreement (CRADA) with the U.S. Federal Bureau of Investigation (FBI) to develop a novel test for its QIAcuity d...